Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2024-009236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Yanyang Nan und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Interleukin-33, Immunotherapy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
Background
The main challenge against patients with cancer to derive benefits from immune checkpoint inhibitors targeting PD-1/PD-L1 appears to be the immunosuppressive tumor microenvironment (TME), in which IL-33/ST2 signal fulfills critical functions. However, whether IL-33 limits the therapeutic efficacy of anti-PD-L1 remains uncertain.
Methods
Molecular mechanisms of IL-33/ST2 signal on anti-PD-L1 treatment lewis lung carcinoma tumor model were assessed by RNA-seq, ELISA, WB and immunofluorescence (IF). A sST2-Fc fusion protein was constructed for targeting IL-33 and combined with anti-PD-L1 antibody for immunotherapy in colon and lung tumor models. On this basis, bifunctional fusion proteins were generated for PD-L1-targeted blocking of IL-33 in tumors. The underlying mechanisms of dual targeting of IL-33 and PD-L1 revealed by RNA-seq, scRNA-seq, FACS, IF and WB.
Results
After anti-PD-L1 administration, tumor-infiltrating ST2 + regulatory T cells (Tregs) were elevated. Blocking IL-33/ST2 signal with sST2-Fc fusion protein potentiated antitumor efficacy of PD-L1 antibody by enhancing T cell responses in tumor models. Bifunctional fusion protein anti-PD-L1-sST2 exhibited enhanced antitumor efficacy compared with combination therapy, not only inhibited tumor progression and extended the survival, but also provided long-term protective antitumor immunity. Mechanistically, the superior antitumor activity of targeting IL-33 and PD-L1 originated from reducing immunosuppressive factors, such as Tregs and exhausted CD8 + T cells while increasing tumor-infiltrating cytotoxic T lymphocyte cells.
Conclusions
In this study, we demonstrated that IL-33/ST2 was involved in the immunosuppression mechanism of PD-L1 antibody therapy, and blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce potent antitumor effect, highlighting the potential therapeutic strategies for the tumor treatment by simultaneously targeting IL-33 and PD-L1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China.
- College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, Michigan, USA.
- Department of pharmacy, Shanghai Children’s Hospital, School of medicine, Shanghai Jiao Tong University, Shanghai, China dianwenju@fudan.edu.cn binxuewang@sjtu.edu.cn xuyaozhang@fudan.edu.cn.
- Shanghai Jiao Tong University, Shanghai, China dianwenju@fudan.edu.cn binxuewang@sjtu.edu.cn xuyaozhang@fudan.edu.cn.
ORCID-Profile: Xuyao Zhang, Dianwen Ju
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Sailing Program
Zitieren
APA
Nan, Y., Bai, Y., Hu, X., Zhou, K., Wu, T., Zhu, A., Li, M., Dou, Z., Cao, Z., Zhang, X., Xu, S., Zhang, Y., Lin, J., Zeng, X., Fan, J., Zhang, X., Wang, X., & Ju, D. (2024). Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009236
Vancouver
Nan Y, Bai Y, Hu X, Zhou K, Wu T, Zhu A, et al. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009236
BibTeX
@article{Nan2024,
author = {Nan, Yanyang and Bai, Yu and Hu, Xiaozhi and Zhou, Kaicheng and Wu, Tao and Zhu, An and Li, Mengyang and Dou, Zihan and Cao, Zhonglian and Zhang, Xumeng and Xu, Shuwen and Zhang, Yuanzhen and Lin, Jun and Zeng, Xian and Fan, Jiajun and Zhang, Xuyao and Wang, Xuebin and Ju, Dianwen},
title = {Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2024-009236}
}
EUVIMED